Calidi Biotherapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
29
- Stock Symbol
-
CLDI
- Investments
-
1
- Share Price
-
$0.51
- (As of Thursday Closing)
Calidi Biotherapeutics General Information
Description
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Contact Information
Website
www.calidibio.comCorporate Office
- 4475 Executive Drive
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 4475 Executive Drive
- Suite 200
- San Diego, CA 92121
- United States
Calidi Biotherapeutics Timeline
Calidi Biotherapeutics Stock Performance
As of 19-Nov-2026, Calidi Biotherapeutics’s stock price is $0.51. Its current market cap is $1.74M with 3.45M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.51 | $0.53 | $0.50 - $24.80 | $1.74M | 3.45M | 101K | -$0.76 |
Calidi Biotherapeutics Financials Summary
As of 30-Sep-2026, Calidi Biotherapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,805 | 1,599 | 29,284 | 53,151 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (14,101) | (18,190) | (19,727) | (26,875) |
| Net Income | (15,970) | (19,906) | (22,143) | (29,216) |
| Total Assets | 5,523 | 8,857 | 14,182 | 10,019 |
| Total Debt | 1,024 | 2,564 | 7,036 | 7,236 |
Calidi Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Calidi Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Calidi Biotherapeutics Comparisons
Industry
Financing
Details
Calidi Biotherapeutics Competitors (3)
One of Calidi Biotherapeutics’s 3 competitors is Minerva Biotechnologies, a Venture Capital-Backed company based in Woburn, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Minerva Biotechnologies | Venture Capital-Backed | Woburn, MA | ||||
| Vor Biopharma | Formerly VC-backed | Boston, MA | ||||
| BioEclipse Therapeutics | Venture Capital-Backed | Mountain View, CA |
Calidi Biotherapeutics Patents
Calidi Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-7329593-B2 | An enhanced system for cell-mediated oncolytic virus therapy | Active | 06-Nov-2018 | ||
| JP-2022520298-A | Enhanced system for the treatment of cell-mediated oncolytic viruses | Active | 06-Nov-2018 | ||
| JP-2023166382-A | Enhanced systems for cell-mediated oncolytic viral therapy | Active | 06-Nov-2018 | ||
| WO-2020097269-A1 | Enhanced systems for cell-mediated oncolytic viral therapy | Inactive | 06-Nov-2018 | ||
| JP-2021531737-A | Cell-based medium for enhancing viral therapy | Active | 04-Jun-2018 | C12N5/0667 |
Calidi Biotherapeutics Signals
Calidi Biotherapeutics Acquisitions (1)
Calidi Biotherapeutics’s most recent deal was a Merger/Acquisition with First Light Acquisition Group. The deal was made on 12-Sep-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| First Light Acquisition Group | 12-Sep-2023 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Calidi Biotherapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Calidi Biotherapeutics FAQs
-
When was Calidi Biotherapeutics founded?
Calidi Biotherapeutics was founded in 2014.
-
Where is Calidi Biotherapeutics headquartered?
Calidi Biotherapeutics is headquartered in San Diego, CA.
-
What is the size of Calidi Biotherapeutics?
Calidi Biotherapeutics has 29 total employees.
-
What industry is Calidi Biotherapeutics in?
Calidi Biotherapeutics’s primary industry is Drug Discovery.
-
Is Calidi Biotherapeutics a private or public company?
Calidi Biotherapeutics is a Public company.
-
What is Calidi Biotherapeutics’s stock symbol?
The ticker symbol for Calidi Biotherapeutics is CLDI.
-
What is the current stock price of Calidi Biotherapeutics?
As of 19-Nov-2026 the stock price of Calidi Biotherapeutics is $0.51.
-
What is the current market cap of Calidi Biotherapeutics?
The current market capitalization of Calidi Biotherapeutics is $1.74M.
-
Who are Calidi Biotherapeutics’s competitors?
Minerva Biotechnologies, Vor Biopharma, and BioEclipse Therapeutics are competitors of Calidi Biotherapeutics.
-
What is Calidi Biotherapeutics’s annual earnings per share (EPS)?
Calidi Biotherapeutics’s EPS for 12 months was -$0.76.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process